Aurobindo Pharma Ltd.

NSE: AUROPHARMA | BSE: 524804 | ISIN: INE406A01037 | Industry: Pharmaceuticals
| Value Stock, Under Radar
1165.6000 17.80 (1.55%)
NSE May 29, 2025 12:19 PM
Volume: 813.7K
 

logo
Aurobindo Pharma Ltd.
06 Jun 2016
1165.60
1.55%
Economic Times
The company paid its CEO, M Govindarajan, an average annual compensation of Rs 9.5 crore, which is above the average CEO salary during the period.
Axis Direct released a Buy report for Aurobindo Pharma Ltd. with a price target of 1500.0 on 28 May, 2025.
Aurobindo Pharma gets best value from payout to CEO in 3 years
Economic Times | 06 Jun 2016
More from Aurobindo Pharma Ltd.
Recommended
Market trades flat, Natco Pharma's net profit grows 5.3% YoY to Rs 406.6 crore in Q4
Trendlyne Marketwatch | 29 May 2025, 12:09PM
Capital markets consider India as US turns volatile | Screener: Stocks with high debt and interest payments
The Baseline | 28 May 2025, 11:08PM
A deal is called off, increasing the chance for Aurobindo Pharma to be debt free
| 15 Jul 2020